Haemonetics Reports Strong Q3 Profit Growth and EPS Despite Revenue Decline, Details Vivasure Acquisition and Share Repurchases

summarizeResumen

Haemonetics Corporation demonstrated robust profitability in the third quarter and first nine months of fiscal 2026, with significant increases in net income and diluted EPS, driven by pricing benefits and decreased restructuring costs. This performance occurred despite a decline in net revenues, primarily due to the divestiture of the Whole Blood product line and a customer transition in the Plasma segment. The filing also provides further details on the recently completed Vivasure Medical acquisition, which expands the Hospital business unit, and outlines substantial share repurchases under the new $500 million program, signaling confidence in future value. Investors should note the ongoing patent litigation, which introduces some uncertainty, and the intangible asset impairment, though overall financial health appears strong.

check_boxEventos clave

• Strong Profitability Growth

  Net income increased by 19.3% to $44.7 million for the quarter and 7.1% to $117.5 million for the nine months. Diluted EPS rose 28.4% to $0.95 for the quarter and 15.0% to $2.46 for the nine months, driven by pricing benefits and cost reductions.

• Revenue Decline

  Net revenues decreased by 2.7% to $339.0 million for the quarter and 4.1% to $987.7 million for the nine months, primarily due to the divestiture of the Whole Blood product line and a customer transition in the Plasma segment.

• Vivasure Medical Acquisition Details

  The company completed the acquisition of Vivasure Medical for an upfront consideration of $116.4 million on January 9, 2026, expanding its Hospital business unit. This follows the 8-K announcement on 2026-01-09.

• Substantial Share Repurchases

  Haemonetics repurchased $75.0 million of common stock in September 2025 and an additional $25.0 million in Q4 fiscal 2026, with $400.0 million remaining under the 2025 share repurchase program.

auto_awesomeAnalisis

Haemonetics Corporation demonstrated robust profitability in the third quarter and first nine months of fiscal 2026, with significant increases in net income and diluted EPS, driven by pricing benefits and decreased restructuring costs. This performance occurred despite a decline in net revenues, primarily due to the divestiture of the Whole Blood product line and a customer transition in the Plasma segment. The filing also provides further details on the recently completed Vivasure Medical acquisition, which expands the Hospital business unit, and outlines substantial share repurchases under the new $500 million program, signaling confidence in future value. Investors should note the ongoing patent litigation, which introduces some uncertainty, and the intangible asset impairment, though overall financial health appears strong.